MX2017006422A - Compositions for treating acute, post-operative, or chronic pain and methods of using the same. - Google Patents

Compositions for treating acute, post-operative, or chronic pain and methods of using the same.

Info

Publication number
MX2017006422A
MX2017006422A MX2017006422A MX2017006422A MX2017006422A MX 2017006422 A MX2017006422 A MX 2017006422A MX 2017006422 A MX2017006422 A MX 2017006422A MX 2017006422 A MX2017006422 A MX 2017006422A MX 2017006422 A MX2017006422 A MX 2017006422A
Authority
MX
Mexico
Prior art keywords
compositions
post
methods
operative
treating acute
Prior art date
Application number
MX2017006422A
Other languages
Spanish (es)
Inventor
Chen Xi
M Criscione Jason
m reynolds Francis
DAI Haining
B Werth Nicholas
a armstrong Patrick
Samuel Langer Robert
Original Assignee
Pixarbio Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pixarbio Corp filed Critical Pixarbio Corp
Publication of MX2017006422A publication Critical patent/MX2017006422A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

Provided herein are compositions for treating acute, chronic, or post-operative pain in a subject, said compositions comprising an anticonvulsant agent and a biodegradable carrier, wherein the agent is incorporated within the biodegradable carrier. Methods of treating pain in a subject and kits for producing compositions for treating acute, chronic or post-operative pain in in a subject are also disclosed herein.
MX2017006422A 2014-11-18 2015-11-11 Compositions for treating acute, post-operative, or chronic pain and methods of using the same. MX2017006422A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462081162P 2014-11-18 2014-11-18
PCT/US2015/060093 WO2016081236A1 (en) 2014-11-18 2015-11-11 Compositions for treating acute, post-operative, or chronic pain and methods of using the same

Publications (1)

Publication Number Publication Date
MX2017006422A true MX2017006422A (en) 2017-09-12

Family

ID=55960737

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017006388A MX2017006388A (en) 2014-11-18 2015-02-23 Compositions for treating acute, post-operative, or chronic pain and methods of using the same.
MX2017006422A MX2017006422A (en) 2014-11-18 2015-11-11 Compositions for treating acute, post-operative, or chronic pain and methods of using the same.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017006388A MX2017006388A (en) 2014-11-18 2015-02-23 Compositions for treating acute, post-operative, or chronic pain and methods of using the same.

Country Status (10)

Country Link
US (3) US20160136179A1 (en)
EP (2) EP3220955A4 (en)
JP (2) JP2017537881A (en)
CN (2) CN107206097A (en)
AU (2) AU2015350554A1 (en)
BR (2) BR112017010430A2 (en)
CA (2) CA2967287A1 (en)
IL (2) IL251881A0 (en)
MX (2) MX2017006388A (en)
WO (3) WO2016081022A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170239183A1 (en) * 2016-02-23 2017-08-24 PixarBio Corporation COMPOSITIONS COMPRISING NAv1.7 SELECTIVE INHIBITORS FOR TREATING ACUTE, POST-OPERATIVE, OR CHRONIC PAIN AND METHODS OF USING THE SAME
CN106902095B (en) * 2017-03-08 2021-11-05 东北林业大学 A baicalin-loaded nanometer preparation integrating chemotherapy and immunotherapy, and its preparation method
US11571429B2 (en) * 2017-05-23 2023-02-07 Upexmed Co. Ltd. Method and compounds for treating peripheral neuropathy
US20180338929A1 (en) * 2017-05-23 2018-11-29 Soon Kap Hahn Method and Compounds for Treating Peripheral Neuropathy

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166800A (en) * 1977-08-25 1979-09-04 Sandoz, Inc. Processes for preparation of microspheres
IL86211A (en) * 1987-05-04 1992-03-29 Ciba Geigy Ag Oral forms of administration for carbamazepine in the forms of stable aqueous suspension with delayed release and their preparation
US5948384A (en) * 1990-09-14 1999-09-07 Syngenix Limited Particulate agents
US20030056896A1 (en) * 1995-05-12 2003-03-27 Frank Jao Effective therapy for epilepsies
ATE267587T1 (en) * 1995-06-09 2004-06-15 Euro Celtique Sa FORMULATIONS AND METHODS FOR PROLONGED LOCAL ANESTHESIA
CA2547531C (en) * 2002-11-26 2013-11-12 Seacoast Neuroscience, Inc. Buoyant polymer particles for delivery of therapeutic agents to the central nervous system
JP2008509933A (en) * 2004-08-13 2008-04-03 エミスフェアー・テクノロジーズ・インク Pharmaceutical formulation comprising microparticles or nanoparticles of a delivery agent
MX2007006777A (en) * 2004-12-06 2007-08-06 Avigen Inc Ibudilast for treating neuropathic pain and associated syndromes.
US20100204178A1 (en) * 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
JP2009533455A (en) * 2006-04-12 2009-09-17 マサチューセッツ インスティテュート オブ テクノロジー Compositions and methods for inhibiting adhesions
US20070253994A1 (en) * 2006-04-28 2007-11-01 Medtronic, Inc. Intraspinal Drug Delivery Methods and Devices To Alleviate Chronic Pelvic Pain
CA2652280C (en) * 2006-05-15 2014-01-28 Massachusetts Institute Of Technology Polymers for functional particles
US20110052697A1 (en) * 2006-05-17 2011-03-03 Gwangju Institute Of Science & Technology Aptamer-Directed Drug Delivery
GB0625322D0 (en) * 2006-12-19 2007-01-24 Pharmakodex Ltd Pharmaceutical compositions
US8293239B2 (en) * 2008-03-04 2012-10-23 Pfizer Limited Methods of treating chronic pain
CN102083419A (en) * 2008-07-01 2011-06-01 日东电工株式会社 Pharmaceutical composition containing surface-coated microparticles
EP2460539A4 (en) * 2009-07-31 2013-12-04 Xi An Libang Medical Technology Co Ltd Nanosphere or microsphere drug carrier, preparation method, composition and use thereof
CN102348468B (en) * 2009-07-31 2014-11-05 西安力邦医药科技有限责任公司 Nanosphere or microsphere drug carrier, preparation method, composition and use thereof
WO2012031205A2 (en) * 2010-09-03 2012-03-08 The Brigham And Women's Hospital, Inc. Lipid-polymer hybrid particles
WO2012075451A2 (en) * 2010-12-03 2012-06-07 Warsaw Orthopedic, Inc. Clonidine and gaba compounds in a biodegradable polymer carrier
CN107737100A (en) * 2011-06-14 2018-02-27 哈尔生物药投资有限责任公司 The administration of Benzodiazepine composition
BR112014006596A2 (en) * 2011-09-21 2017-03-28 Yissum Res Dev Co nanoparticle that encapsulates a plurality of nanocarriers, composition, use of a nanoparticle, kit, delivery system, process for obtaining a nanoparticle, and nanoparticle process for obtaining nanoparticles
EP4335505A2 (en) * 2012-11-30 2024-03-13 The Regents of The University of California Anticonvulsant activity of steroids
CN103610664B (en) * 2013-12-11 2015-09-16 中国药科大学 A kind of method preparing carbamazepine Poly(D,L-lactide-co-glycolide microcapsule

Also Published As

Publication number Publication date
EP3220955A4 (en) 2018-07-25
WO2016081022A1 (en) 2016-05-26
US20160136179A1 (en) 2016-05-19
JP2017533943A (en) 2017-11-16
EP3220955A1 (en) 2017-09-27
JP2017537881A (en) 2017-12-21
IL251881A0 (en) 2017-06-29
EP3220917A4 (en) 2018-07-25
AU2015350347A1 (en) 2017-05-04
MX2017006388A (en) 2017-08-21
WO2016081445A1 (en) 2016-05-26
US20160317446A1 (en) 2016-11-03
AU2015350554A1 (en) 2017-04-27
CA2967335A1 (en) 2016-05-26
WO2016081236A1 (en) 2016-05-26
CN107405351A (en) 2017-11-28
IL251880A0 (en) 2017-06-29
CA2967287A1 (en) 2016-05-26
BR112017010428A2 (en) 2017-12-26
CN107206097A (en) 2017-09-26
US20170224621A1 (en) 2017-08-10
EP3220917A1 (en) 2017-09-27
BR112017010430A2 (en) 2017-12-26

Similar Documents

Publication Publication Date Title
PH12020550781A1 (en) Anti-jagged1 antibodies and methods of use
PH12017500877A1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
PH12016501894A1 (en) Anti-ox40 antibodies and methods of use
MX2019007030A (en) Compositions and methods for treating cancer.
GB2538178A (en) Viscosifier polymer for treatment of a subterranean formation
NZ731467A (en) Anti-tim3 antibodies and methods of use
MX2017004579A (en) Soluble fibrous structures and methods for making same.
TW201614068A (en) Fucosidase from bacteroides and methods using the same
PH12015501954A1 (en) Anti-b7-h4 antibodies and immunoconjugates
MX2017003022A (en) Anti-cll-1 antibodies and immunoconjugates.
MX2017007645A (en) Nitrification inhibitor compositions and methods for preparing the same.
AU2016263598A8 (en) Methods and kits for treating depression
EP3642341A4 (en) Two-tailed self-delivering sirna and related methods
EP3252019A4 (en) Method for treating wastewater, and activator for treating wastewater
MX2015013177A (en) Combination cancer treatments utilizing micrornas and egfr-tki inhibitors.
MX2016004802A (en) Anti-rsp02 and/or anti-rsp03 antibodies and their uses.
MX2016009590A (en) Apilimod compositions and methods for using same.
MX2017008414A (en) Nitrification inhibitor compositions and methods for preparing the same.
GB2569488A (en) PD-1 specific aptamers
MX2017006422A (en) Compositions for treating acute, post-operative, or chronic pain and methods of using the same.
MX2017000141A (en) Targeted therapeutic nanoparticles and methods of making and using same.
MX2015013021A (en) 5-bromo-indirubins.
MX2017009180A (en) Multi-phase bacterially-synthesized-nanocellulose biomaterials and method for producing the same.
PH12017501022B1 (en) Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same
MX2017001985A (en) Compositions for inhibiting inflammation in a subject with a spinal cord injury and methods of using the same.